Pacific Biosciences of California (PACB) EV/EBITDA: History & Chart

Pacific Biosciences of California, Inc.(PACB)

Medical - Devices · Menlo Park, CA

$2.72-0.16 (-5.40%)

Delayed quote: Oct 6, 2026, 2:45 PM EDT

About Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

Menlo Park, CA

485 employees

www.pacb.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Mark Van Oene

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Pacific Biosciences of California, Inc. (PACB)	$843.28M	N/A	N/A	N/A	N/A
SpyGlass Pharma, Inc. Common Stock (SGP)vs ›	$840.68M	N/A	N/A	N/A	N/A
QuidelOrtho Corporation (QDEL)vs ›	$842.16M	N/A	19.31x	12.44x	8.61x
Beta Bionics, Inc. (BBNX)vs ›	$838.83M	N/A	N/A	N/A	N/A
Alumis Inc. (ALMS)vs ›	$837.55M	N/A	N/A	N/A	N/A
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$835.44M	N/A	45.75x	45.75x	45.75x
SL Science Holding Ltd (SLBT)vs ›	$857.96M	N/A	N/A	N/A	N/A
SI-BONE, Inc. (SIBN)vs ›	$856.52M	N/A	N/A	N/A	N/A
Rigel Pharmaceuticals, Inc. (RIGL)vs ›	$863.17M	9.39x	6.28x	11.56x	11.56x
Ardelyx, Inc. (ARDX)vs ›	$813.96M	N/A	7.99x	7.99x	7.99x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Pacific Biosciences of California, Inc. (PACB)

$843.28M

N/A

SpyGlass Pharma, Inc. Common Stock (SGP)vs ›

$840.68M

N/A

QuidelOrtho Corporation (QDEL)vs ›

$842.16M